SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT 1934

DATE OF REPORT: AUGUST 11, 2003

TITAN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)

DELAWARE	*0-27436*	*94-3171940*
(State or other jurisdiction of incorporation)	*(Commission File Number)*	*(IRS Employer Identification No.)*

400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO, CALIFORNIA 94080
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (650) 244-4990

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits

99.1 Press Release dated August 11, 2003 - Titan Reports Second Quarter 2003 Results

ITEM 9. REGULATION FD DISCLOSURE

In accordance with the interim guidance of the Securities and Exchange Commission, the Company is furnishing the information required by Item 12 of Form 8-K (Results of Operations and Financial Condition) under "Item 9 Regulation FD Disclosure" and information contained in this report (including exhibits hereto) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liability of that section and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended.

On August 11, 2003, the Company issued a press release announcing its results of operations and financial condition for the three and six months ended June 30, 2003. The full text of the press release is set forth in Exhibit 99.1 attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TITAN PHARMACEUTICALS, INC.

By: /s/ Robert E. Farrell

Robert E. Farrell, Executive Vice President and Chief Financial Officer

Dated: August 11, 2003

Titan Pharmaceuticals, Inc.

EXHIBIT 99.1

Company:	*Media:*	*Investors:*
Robert Farrell	*Mark Padgett*	*Dawn Lauer*
Executive Vice President & CFO	*GCI Group*	*GCI Group*
650-244-4990	*212-537-8082*	*212-537-8088*

TITAN REPORTS SECOND QUARTER 2003 RESULTS

SOUTH SAN FRANCISCO, CA - AUGUST 11, 2003 - Titan Pharmaceuticals, Inc. (ASE: TTP) today announced financial results for the second quarter ended June 30, 2003.

Operating expenses for the second quarter of 2003 were approximately $7.0 million compared with operating expenses of $8.3 million for the second quarter of 2002. For the first six months of 2003, operating expenses were approximately $14.0 million, a reduction of approximately $3.0 million compared with operating expenses of $17.0 million for the first six months of 2002.

Net loss for second quarter 2003 was approximately $6.7 million, or $0.24 per share, compared to a net loss of $7.0 million, or $0.25 per share, for the second quarter in 2002. For the first 6 months of 2003, net loss was $13.2 million or $0.48 per share, compared to a net loss of $12.0 million or $0.43 per share, for the same six-month period in 2002.

Revenues for the first six months of 2003 were approximately $28,000, compared to $2.5 million for the same six-month period in 2002. The difference in revenue is primarily the result of a milestone payment Titan received from Schering AG for Spheramine(R) in the first quarter of 2002.

Interest income, net of other expenses, for second quarter 2003 was approximately $309,000 compared to $1.1 million for second quarter 2002, primarily reflecting a decline in interest rates, and a lower balance of cash and marketable securities. For the first six months of 2003, interest income, net of other expenses, was $776,000 compared to $2.5 million for the same six-month period in 2002. At June 30, 2003, the Company had approximately $59.6 million in cash, cash equivalents and marketable securities.

"Our operating results indicate that we continue to achieve significant quarter-over-quarter reductions in operating expenditures," stated Dr. Louis R. Bucalo, Chairman, President and CEO. "These reductions were made while significantly advancing our four core product programs in clinical testing. We look forward to further advancing these core programs during the second half of the year."

Following is an update on the status and progress of Titan's core development programs:

SPHERAMINE
Enrollment in a randomized, controlled, blinded, multi-center Phase IIb clinical study of Spheramine in advanced Parkinson's disease is proceeding on schedule, and the first cohort of twelve patients has been enrolled. Schering AG, Germany, Titan's corporate partner for the development of Spheramine, is funding and co-managing the study. In the second quarter, results from a pilot clinical study of Spheramine, demonstrating an average 41 percent improvement in patients' motor function 2 years post treatment, were presented at the American Academy of Neurology.

PIVANEX
A randomized, controlled, multi-center Phase IIb clinical study of Pivanex in combination with docetaxel in the treatment of non-small cell lung cancer (NSCLC) was initiated in June. Pivanex is being administered at the same dose level at which it demonstrated encouraging tumor response and survival data in a previous Phase II clinical study, in which Pivanex was administered as a single agent. In related development activities, additional laboratory study results demonstrating that Pivanex is synergistic with docetaxel against NSCLC were presented at the meeting of the American Association for Cancer Research in July. Pivanex is a histone deacetylase inhibitor with potential activity in a wide range of cancers.

GALLIUM MALTOLATE
Titan is completing the Phase I portion of a Phase I/II clinical study of gallium maltolate in several cancers. There have been no significant adverse events, and the maximum tolerated dose level has not yet been reached. Accordingly, additional patient cohorts are being enrolled at higher doses. Preclinical testing of gallium maltolate in other disease settings is also ongoing. Gallium maltolate is a novel oral agent for the treatment of cancer and bone disease.

PROBUPHINE
Titan is advancing a pilot clinical study of Probuphine, a novel long-term treatment for opiate addiction that utilizes Titan's proprietary ProNeura drug delivery system. The first cohort of six patients has been enrolled at the first dose level being studied, with no adverse effects seen to date. Probuphine has been shown in preclinical studies to deliver targeted therapeutic levels of buprenorphine, an approved agent for the treatment for opiate addiction, for eight months with no adverse effects. Results from these preclinical studies were presented at the Meeting of the Controlled Release Society held in Glasgow, Scotland in July 2003.

Conference Call Information:

Titan will hold a conference call today at 2:00 PM Eastern Daylight Time to discuss the Company's financial results for the second quarter and first six months of the year. The conference call will be broadcast live over the Internet at www.titanpharm.com. Webcast listeners should log on at least 10 minutes prior to the scheduled start time of the call to register and download or install any required audio software.

ABOUT TITAN PHARMACEUTICALS

Titan Pharmaceuticals, Inc. (ASE: TTP) is a biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system (CNS) disorders, cancer and other serious and life-threatening diseases. Titan's numerous products in development utilize novel technologies that have the potential to significantly improve the treatment of these diseases. Titan also establishes partnerships with multinational pharmaceutical companies and government institutions for the development of its products.

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets and the Company's ability to obtain additional financing if necessary. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

# # #

<TABLE>

TITAN PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNT)

<CAPTION>

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2003	2002	2003	2002
<S>	*<C>*	*<C>*	*<C>*	*<C>*
		(UNAUDITED)		
License and contract revenue	$ 2	$ 151	$ 28	$ 2,498

Total revenue	*2*	*151*	*28*	*2,498*
Operating expenses:				
Research and development	*5,735*	*6,919*	*11,377*	*14,405*
General and administrative	*1,257*	*1,391*	*2,638*	*2,601*
Total operating expenses	*6,992*	*8,310*	*14,015*	*17,006*
Loss from operations	*(6,990)*	*(8,159)*	*(13,987)*	*(14,508)*
Interest income, net of other expense	*309*	*1,127*	*776*	*2,526*
Net loss	*$ (6,681)*	*$ (7,032)*	*$ (13,211)*	*$ (11,982)*
Basic and diluted net loss per share	*$ (0.24)*	*$ (0.25)*	*$ (0.48)*	*$ (0.43)*
Shares used in computing basic and diluted net loss per share	*27,643*	*27,642*	*27,643*	*27,642*

</TABLE>
<TABLE>

CONDENSED CONSOLIDATED BALANCE SHEETS

<CAPTION>

	JUNE 30, 2003	*DECEMBER 31, 2002*
	(unaudited)	*(Note A)*
<S>	*<C>*	*<C>*
Assets		
Cash, cash equivalents, and marketable securities	*$ 59,641*	*$ 73,450*
Prepaid expenses, receivables, and other current assets	*1,859*	*1,197*
Total current assets	*61,500*	*74,647*
Furniture and equipment, net	*930*	*979*
Investment in other companies	*300*	*300*
	$ 62,730	*$ 75,926*
Liabilities and Stockholders' Equity		
Current liabilities	*$ 3,991*	*$ 3,945*
Minority interest - Series B preferred stock of Ingenex, Inc.	*1,241*	*1,241*
Stockholders' Equity	*57,498*	*70,740*
	$ 62,730	*$ 75,926*

Note A: The balance sheet has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the United States for complete financial statement presentation.
</TABLE>